Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070521 | 0.87 | FFAR1 (0.46) | FFAR4APPTDP1CYP4F2CYP4A11 | |
| SCHEMBL2349977 | 0.83 | PTGER1 (0.47) | FFAR4ABCB1AKR1C3CYP4F2CYP4A11 | |
| SCHEMBL8890494 | 0.81 | APP (0.61) | FFAR4APPAKR1C3FFAR1MRGPRX4 | |
| SCHEMBL6034704 | 0.81 | FFAR4 (0.56) | FFAR4APPALOX5ABCB1AKR1C3 | |
| SCHEMBL2350411 | 0.80 | FFAR1 (0.53) | FFAR4APPALOX5AKR1C3CYP4F2 | |
| SCHEMBL6583603 | 0.80 | APP (0.66) | FFAR4APPALOX5AKR1C3FFAR1 | |
| SCHEMBL5881099 | 0.80 | APP (0.73) | FFAR4APPALOX5FFAR1KDM4E | |
| SCHEMBL3802206 | 0.79 | MMP8 (0.43) | FFAR4APPMRGPRX4KDM4ELMNA | |
| SCHEMBL2350166 | 0.77 | FFAR1 (0.64) | FFAR4APPAKR1C3FFAR1MRGPRX4 | |
| SCHEMBL2349219 | 0.77 | FFAR1 (0.54) | FFAR4APPAKR1C3FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902394-B2 | Calcilytic compounds | GLAXOSMITHKLINE LLC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100029782-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| EP-2120898-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008077009-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029782-A1 | Calcilytic Compounds | CALCR, CALCA, CALCB | FFAR4 3942/4885APP 948/4885ALOX5 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.